ERBB2 and neoplasm: Of the patients with LM and available primary tumor features 173 (22.2 %) patients had HR+/HER2+ BC, 92 (11.8 %) HR-/HER2+, 349 (44.8 %) HR+/HER2-, and 165 (21.2 %) triple-negative BC (TNBC).